Three independent discounted-cash-flow-style models value Aurinia Pharmaceuticals Inc every trading day. 0 of 3 currently price AUPH above its market price.
| Free Cash Flow model | $-279.10 |
| Excess Profit model | $-376.38 |
| Residual Earnings model | $-1.41 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +12.6% |
| Net debt / EBITDA | 0.7× |
| Gross margin | +88.5% |
| Revenue CAGR | +83.8% |
| Cash conversion | 0.5× |
| Dividend yield | — |
| Buyback yield | +6.2% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open AUPH in StockKitty